1999 SESSION

999132309

1

2

3

12

10/14/22 20:57

HOUSE BILL NO. 2428

AMENDMENT IN THE NATURE OF A SUBSTITUTE

(Proposed by the Senate Committee on Education and Health

on February 18, 1999)

(Patron Prior to Substitute—Delegate Jones, S. C.)

4 5 6 7 A BILL to amend and reenact § 54.1-3300 of the Code of Virginia and to amend the Code of Virginia by adding a section numbered 54.1-3300.1, relating to the practice of pharmacy. 8 Be it enacted by the General Assembly of Virginia:

9 1. That § 54.1-3300 of the Code of Virginia is amended and reenacted, and that the Code of 10 Virginia is amended by adding a section numbered 54.1-3300.1 as follows:

11 § 54.1-3300. Definitions.

As used in this chapter, unless the context requires a different meaning:

13 "Board" means the Board of Pharmacy.

14 "Collaborative agreement" means a voluntary, written arrangement between one pharmacist and his 15 designated alternate pharmacists involved directly in patient care at a location where patients receive services and a practitioner of medicine, osteopathy, or podiatry and his designated alternate 16 17 practitioners involved directly in patient care which authorizes cooperative procedures with respect to patients of such practitioners. Collaborative procedures shall be related to treatment using drug therapy, 18 laboratory tests or medical devices, under defined conditions or limitations, for the purpose of 19 20 improving patient outcomes. A collaborative agreement is not required for the management of patients 21 of an inpatient facility.

22 "Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the 23 lawful order of a practitioner, including the prescribing and administering, packaging, labeling or 24 compounding necessary to prepare the substance for delivery. 25

"Pharmacist" means a person holding a license issued by the Board to practice pharmacy.

26 "Pharmacy" means every establishment or institution in which the practice of pharmacy is conducted; 27 drugs, medicines or medicinal chemicals are dispensed or offered for sale, or a sign is displayed bearing the word or words "pharmacist," "pharmacy," "apothecary," "drugstore," "druggist," "drugs," "medicine 28 29 store," "drug sundries," "prescriptions filled," or any similar words intended to indicate that the practice 30 of pharmacy is being conducted.

"Practice of pharmacy" means the personal health service that is concerned with the art and science 31 of selecting, procuring, recommending, administering, preparing, compounding, packaging and dispensing of drugs, medicines and devices used in the diagnosis, treatment, or prevention of disease, 32 33 34 whether compounded or dispensed on a prescription or otherwise legally dispensed or distributed, and 35 shall include the proper and safe storage and distribution of $drugs_{\tau}$; the maintenance of proper records_{τ} 36 and; the responsibility of providing information concerning drugs and medicines and their therapeutic 37 values and uses in the treatment and prevention of disease, and the management of patient care under 38 the terms of a collaborative agreement as defined in this section.

39 Other terms used in the context of this chapter shall be defined as provided in Chapter 34 40 (§ 54.1-3400 et seq.) of this title unless the context requires a different meaning.

41 § 54.1-3300.1. Participation in collaborative agreements; regulations to be promulgated by the 42 Boards of Medicine and Pharmacy.

43 A pharmacist and his designated alternate pharmacists involved directly in patient care may 44 participate with a practitioner of medicine, osteopathy, or podiatry and his designated alternate practitioners involved directly in patient care in collaborative agreements which authorize cooperative 45 procedures related to treatment using drug therapy, laboratory tests or medical devices, under defined 46 47 conditions and/or limitations, for the purpose of improving patient outcomes. No patient shall be **48** required to participate in a collaborative procedure without such patient's consent.

49 Collaborative agreements may include the modification, continuation or discontinuation of drug 50 therapy pursuant to written, patient-specific protocols; the ordering of laboratory tests; or other patient care management measures related to monitoring or improving the outcomes of drug or device therapy. 51 No such collaborative agreement shall exceed the scope of practice of the respective parties. Any 52 53 pharmacist who deviates from or practices in a manner inconsistent with the terms of a collaborative 54 agreement shall be in violation of § 54.1-2902.

Collaborative agreements may only be used for conditions which have protocols that are clinically 55 accepted as the standard of care, or are approved by the Boards of Medicine and Pharmacy. The 56 Boards of Medicine and Pharmacy shall jointly develop and promulgate regulations to implement the 57 provisions of this section and to facilitate the development and implementation of safe and effective 58 59 collaborative agreements between the appropriate practitioners and pharmacists. The regulations shall

HB2428S1

Ŋ

- 60
- include guidelines concerning the use of protocols, and a procedure to allow for the approval or disapproval of specific protocols by the Boards of Medicine and Pharmacy if review is requested by a 61 62 practitioner or pharmacist.
- Nothing in this section shall be construed to supersede the provisions of § 54.1-3303. 63
- 2. That the provisions of this act shall expire on July 1, 2004. 64
- 3. That the Boards of Medicine and Pharmacy shall jointly promulgate regulations to implement 65
- the provisions of this act within 280 days of the date of enactment. No collaborative agreement 66
- shall become effective prior to ninety days after the effective date of the emergency regulations. 67